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ABSTRACT 
 
This thesis is focused on the analysis of protein expression profiles from the airways of sarcoidosis 
patients using quantitative proteomics. Sarcoidosis is a multisystemic inflammatory disorder of unknown 
etiology characterized by the presence of noncaseating granulomas in the affected organs. Previous 
findings in proteomics have reported identification of several proteins that certainly reflect the ongoing 
inflammation response but that did not have any specificity for sarcoidosis disease. The overall aim of 
these studies was therefore to continue searching for new protein candidates that could help us to 
determine the possible mechanisms behind sarcoidosis.  
We first investigated the total protein profile in the lung lumen from two granulomatous disorders, 
sarcoidosis (HLA-DRB1*15 positive), characterized to present an unresolved chronic inflammation 
disease and chronic beryllium disease (CBD) by collecting the bronchoalveolar soluble proteins and 
applying differential gel electrophoresis (DIGE) coupled to mass spectrometry (MS) (paper I). This led to 
the identification of fourteen proteins with altered profiles, some of these related to inflammation (β2-
microglobulin, annexin II, complement C3, apolipoprotein A1, IgG kappa chain and heat shock protein 
70) and the oxidative response (peroxiredoxin 5, hemopexin, α1-antitrypsin and superoxide dismutase), 
hence reflecting the persistent inflammation state in those granulomatous diseases. 
Gel-based 2DE techniques have been claimed to be unreliable in quantitative proteomics. The 
introduction of differential gel electrophoresis (DIGE) in 2DE approches has greatly improves gel-to-
gel variation and the reproducibility; however, other sources of variance have been highlighted. In a 
2D experimental-related study, we investigated the different sources of variance that were intrinsic to 
gel-based proteomics. We measured the technical variance related to background subtraction algorithms 
[4-8%] and the experimental variance related to the 1st and 2nd dimension of 2DE workflow (~30%). In 
addition, we reported the improvement of the 4th generation image software program SameSpotsTM in 
terms of reduced levels of variance introduced from background algorithms, higher levels of accurate 
spot-matching and most importantly an improved objectivity of the analysis (paper II).  
To further evaluate the protein changes in sarcoidosis we investigated the protein profiles from 
purified alveolar macrophages (AM). With the intention to improve both the protein resolution we 
applied two complementary proteomic approaches. First, all soluble AM proteins were resolved using 
the DIGE technique (paper III). Second all membrane-associated proteins (MAP) were then identified 
and quantified using the shotgun proteomic,  liquid chromatography couple to mass spectrometry LC-
MS/MS approach (paper IV). We found similar results from these parallel studies, including several 
pathways altered in sarcoidosis (papers III & IV). In addition, by applying multivariate regression 
analysis we could also identify a robust model with a set of 13 proteins able to discriminate sarcoidosis 
from the healthy group (paper IV). 
Taken together, improvements in gel-based image software and clinical sample pre-treatment 
allow more accurate and quantitative analysis, revealing deeper insight into the proteome. The biological 
findings presented in this thesis give new perspectives in understanding AM and their role in sarcoidosis 
disease as well as the possibility to search for disease biomarkers.     
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1 INTRODUCTION 
 
1.1 THE LUNGS 
The primary function of the respiratory system is to supply the body with oxygen and 
to exchange and exhale carbon dioxide from the blood system by passive diffusion at 
the alveolar levels. The respiratory system can be anatomically divided into the 
proximal conducting airways and the distal respiratory region (i.e. alveolar ducts and 
alveolar airsacs). The average adult's lungs contain about 600 million alveoli that are 
surrounded by capillaries. The inhaled oxygen passes into the alveoli and then diffuses 
through the capillaries into the arterial blood. Meanwhile, the blood from the veins 
releases its carbon dioxide into the alveoli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure I. Illustration of the anatomic Lung structure 
 
  
1.2 INNATE IMMUNITY  
The innate immune system is our first line of defense against invading organisms. The 
process of phagocytosis involves a variety of receptors and here I briefly present three 
of main systems: the Fcγ receptors, the complement receptors, and Toll-like receptors 
relevant for optimal initiation of innate responses.  
 
1.2.1 Fcγ receptors  
Immunoglobulin Fc receptors (FcRs) play a crucial role in immune defense by 
providing a link between antibody–antigen complexes and cellular phagocyte effector 
machinery. Antibody opsonization is the process through which a pathogen is marked 
for ingestion and destruction by AMs or other phagocytes1. Binding of immune-
complexes to FcRs activates effector cells leading to phagocytosis, endocytosis of IgG-
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opsonized particles, the release of inflammatory mediators and antibody-dependent 
cellular cytotoxicity 2-5. FcRs have been described for all classes of immunoglobulins6; 
herein I only focus on FcγR since it is relevant in the studies performed in this thesis. 
Three subclasses of receptors (A,B and C) are known for FcγRI and FcγRII, and two 
subclasses A and B are described for FcγRIII7. All Fcγ receptors have high degrees of 
sequence identity but differ significantly in their cytoplasmic domains8 which are 
decisive in directing downstream cellular signaling. 
 
1.2.2 Complement receptors  
The complement system encompasses a biochemical cascade which promotes the 
ability of IgG antibodies to clear pathogens. Phagocytic cells have a receptor for 
complement component such as C3b. Binding of C3b-coated bacteria to this receptor 
results in enhanced phagocytosis and stimulation of the respiratory burst. Activation of 
the complement cascade promotes clearance of dead cells or antibody complexes. 
These complement components are deposited on the cell surface of the pathogen and 
aid in its destruction9-12.  
 
1.2.3 Toll-like receptors  
Phagocytes have a variety of Toll-like receptors (TLRs) which are a class of Pattern 
Recognition Receptors (PRRs) able to recognize broad three-dimensional molecular 
patterns termed PAMPs (pathogen-associated molecular patterns) on infectious 
agents13-15. PAMP structures recognized by TLRs include lipids, lipoproteins, proteins 
and nucleic acids derived from a wide range of microbes for instance bacteria, viruses 
and parasites. The TLRs are divided into two subsets depending on their cellular 
localization and the specificity of their PAMP recognition. The first group TLRs are 
expressed on cell surfaces and comprise of TLR1, TLR2, TLR4, TLR5, TLR6 and 
TLR11, those primarily recognizing microbial membrane components14,16,17. The other 
group TLRs are expressed on intracellular vesicles (endoplasmic reticulum, endosomes, 
and lysosomes) and includes TLR3, TLR7, TLR8 and TLR9, recognizing microbial 
nucleic acids18-20. Binding of these exogenous agents via Toll-like receptors results in 
activation of phagocytosis, the respiratory burst and the release of inflammatory 
cytokines such as IL-1, TNF-alpha and IL-6 by the phagocytes16,21.  
 
1.2.4 Macrophages 
The mononuclear phagocytic system consists of blood monocytes and tissue 
macrophages. Monocytes circulate in the blood for up to 48 hours, whereas 
macrophages have a longer life span, about 90 days, and display a wide heterogeneity 
of activities. AMs represent the initial line of protection against inhaled 
microorganisms, and other toxins agents. They express a broad range of plasma 
membrane receptors which mediate interaction with microorganisms based on the 
recognition of conserved PAMPs16,22. PAMP recognition leads to activation of 
intracellular signaling cascades and ultimately results in a pro-inflammatory response 
and further activation of both the innate and adaptive immune systems23. Indeed, AMs 
play a role in the induction and regulation of adaptive immune responses24, e.g. they 
work as competent antigen presenting cells (APCs) in the lungs25 and have been linked 
to the pathogenesis of multiple lung diseases such as COPD and sarcoidosis26-29. 
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1.2.5 Neutrophils 
Neutrophils, also known as granulocytes, are essential in host defense against microbial 
pathogens30. They constantly circulate in the blood and are recruited to the infection 
site by gradient of chemokines (complement C5a and interleukin-8) and recognize 
pathogens using TLRs. Upon activation neutrophils produce superoxide anion (O·2), 
hydrogen peroxide (H2O2) and other reactive oxygen species (ROS) together with 
microbicidial peptides and proteases.  
 
1.2.6 Dendritic cells 
Dendritic cells (DC) are bone-marrow-derived leucocytes present in most tissues and 
mainly in the epithelium (known as Langerhans cells). They are one link between the 
innate and adaptive systems. DCs are specialized APCs capable of stimulating primary 
T-cell response to specific antigens. The main function of DCs is to phagocytose 
pathogens, migrate to peripheral lymph nodes and present pathogen antigens to T-cells 
using the MHC II molecules.  
 
1.3 ADAPTIVE IMMUNITY 
The adaptive immune response is antigen-specific and complementary to the innate 
response. It is active approximately after 4 to 5 days of an infection. Although this may 
seem as a slow response, it is specific to the invading pathogen and very powerful. The 
effector cells of the adaptive immune response include antigen presenting cells 
(macrophages and dendritic cells (DCs)) which interact with lymphocytes (T and B 
lymphocytes). Accordingly, the adaptive response can be subdivided into a cell-
mediated immune response (including T lymphocytes and APC) and humoral immune 
mediated response (including B cells and soluble secreted antibodies). T and B cells 
work as complementary mechanisms and differ in the way they recognize antigens. 
While the B cell-mediated humoral response is directed against soluble exogenous 
proteins (antigens), T lymphocytes mainly detect protein fragments (peptides) as they 
are presented by specialized molecules called major histocompatibility complex 
(MHC). 
 
1.3.1 MHC and antigen presentation 
Major histocompatibility complex (MHC) is a large genomic region on chromosome 6 
of about 3.6 Mb (3 600 000 base pairs) including 140 genes, where half of them encode 
for human leukocyte antigen (HLA) genes. The classical MHC molecules are also 
referred to as HLA molecules in humans. There are two classes of MHC molecules, 
MHC class- I and class II.  
MHC class I molecules are expressed on every nucleated cell and has the 
function to bind peptides and display them on the plasma membrane. MHC I loads 
peptides of intracellular origin generated in the proteasome system. MHC I molecules 
consist of a heterodimer polypeptide, the α-chain and β2-microglobulin. There are three 
class I genes (HLA-A, HLA-B, and HLA-C), so it means that any cell can express at 
most 6 different MHC-I molecules. Due to central and peripheral tolerance mechanisms 
cells presenting endogenous proteins will be ignored whereas infected cells containing 
foreign proteins will be destroyed. MHC I bound to a microbial peptide (about 8-10 
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amino acids), interact with cytotoxic CD8+ T Lymphocyte (CTLs) and this lead to cell 
destruction. Hence, CTLs are important in clearing intracellular infections.  
MHC class II molecules are found on professional antigen-presenting cells (APC) 
such as macrophages, dendritic cells (DCs), B-cells and also activated T cells. They are 
specialized to exclusively present exogenous peptides to CD4+ T cells. MHC II is a 
heterodimer composed of α- and a β- chain. There are three MHC II genes used for 
antigen presentation; HLA-DP, HLA-DQ, HLA-DR, and two other genes used for 
loading antigens on the MHC molecule (HLA-DM, HLA-DO). The size of the peptide 
loaded on the MHC II molecule is about 13-20 amino acid. HLA-genes which are 
highly polymorphic within a population, have been linked to different disorders, for 
instance it has been shown that the MHC genes are important to the disease outcome in 
sarcoidosis.  
 
1.3.2 T cells 
T lymphocytes play a central role in cell mediated immunity. They interact with other 
cells by using the cell surface T cell receptor (TCR). There are several types of T cells 
and can be divided based on their specific function; T helper cells (Th cells), T 
regulatory cells (Treg cells) and T cytotoxic cells (CTLs). 
Th-cells also known as CD4+ T-cells help other cells through the release of 
cytokines. They are able to assist the maturation of B cells as well as activation of 
CTLs and macrophages. Depending on the cytokines released they are categorized as 
Th1, Th2 and Th17 cells, as well as Treg cells. Th1 release pro-inflammatory cytokines 
including IL-2 and IFN-gamma that activate macrophages, thereby increasing the 
antimicrobial action, and stimulate the release of IgG important for the opsonisation 
and clearance of pathogens. Th2 cytokines include IL-4, IL-5, IL-10, and IL-13 and 
mediate class switching in B cells to IgE production as well as eosinophil activation. 
Th17 cells are more recently discovered and considered important for various 
autoimmune conditions. Treg cells negatively regulate other T cells through the release 
of IL-10 and TGF-β, and/or through direct cell-cell interaction.  
Cytotoxic T cells or killer T cells induce death of infected somatic cells. CTLs 
uses T-cell receptors (TCR) and the CD8 receptor to recognized specific antigens 
bound to MHC class I molecules. When exposed to infected cells, CTLs release 
perforin, granulysin and granzymes to disrupt the plasma membrane of the target cell 
creating pores and allowing serine and cysteine proteases to enter the cell, activate the 
caspase cascade and lead to programmed cell death. In addition, CTLs also express 
FASL that binds to Fas on target cells to induce apoptosis. 
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1.4 SARCOIDOSIS 
 
1.4.1 Epidemiology 
Sarcoidosis is a systemic inflammatory disease of unknown etiology, most commonly 
involving the lungs, skin, lymph nodes and eyes. Sarcoidosis affects people of all ethnic 
groups, often middle-aged adults. The incidence of sarcoidosis varies globally, 
probably because of differences in environmental exposures and predisposing genetic 
factors such as HLA alleles among others. The highest incidence of sarcoidosis has 
been observed in northern European countries (5-40 cases per 100,000 people)31,32. In 
Japan the annual incidence ranges from 1-2 cases per 100,000 people33. In USA the 
incidence among black Americans is about three times higher than that among white 
Americans (35.5 versus 10.9 cases per 100,000 people)34. In Sweden the incidence of 
sarcoidosis is about 15-20 per 100,000 individuals per year and it usually affects 
individuals between the ages of 20-40 years-old35. Epidemiological studies support the 
idea of environmental exposure to be important for developing sarcoidosis. Work-
related risks for sarcoidosis for nurses36,37 and season-related clustering38,39 support a 
transmissibility aspect in sarcoidosis.  
 
1.4.2 Etiology 
Sarcoidosis has primarily been suspected to be an infectious disease. Although there are 
studies demonstrating the presence of microbial proteins, or DNA in granuloma of 
patients, none has been convincingly proven to be causative. Studies in Japanese 
population have reported the presence of Propionibacterium acnes in the 
bronchoalveolar lavage of sarcoidosis 40 41 as well as in granulomas biopsy samples of 
lymph nodes 42,43. Mycobacterium tuberculosis has also been suggested as a possible 
candidate44,45. Systemic cellular responses to M. tuberculosis have been reported in 
sarcoidosis46, and it has recently been reported that alveolar T-cells respond to different 
mycobacterial antigens47,48. In particular, the mycobacterial mkatG protein which was 
identified in granulomatous tissue of sarcoidosis patients48 has been shown to be 
associated with both circulating anti-mKatG antibodies as well as anti-mKatG specific 
T cell responses in about 50% of sarcoidosis patients45. A meta-analysis of biopsies 
further support the presence of mycobacterial DNA in over 26% of sarcoidosis cases49. 
Additionally, autoimmune reactivity has also been reported; one study from our own 
group demonstrated immune reactivity to the self-protein vimentin in sarcoidosis 
patients50.   
   
1.4.3 Genetics 
The genetic background is important for the development of sarcoidosis and also for 
the disease outcome. A genome wide scan analysis including 63 German sarcoidosis 
families was performed and identified the most prominent peak at the chromosome 6p, 
i.e. in the MHC region51 Also, several studies showed associations between sarcoidosis 
and various HLA gene polymorphisms. In an American study, HLA-DRB1*11 and 
HLA-DPB1*01 were reported as risk factors for both black and white Americans52. In 
our own group, we have found HLA-DRB1*03 positive patients to associate with a 
self-resolving disease within 2 years time53, whereas patients having HLA-DRB1*14 
and 15 are instead to associated with a prolonged unresolved disease54. 
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In addition to HLA genes, there are other genes that appear as a strong factors for 
sarcoidosis, such as annexin A1155,56 as well as other more controversial BTNL257,58.  
 
1.4.4 Pathology 
A T cell alveolitis is characteristic for sarcoidosis; especially the increase of CD4+ T-
cells with a subsequently increased CD4/CD8 ratio >3.5 is specific for sarcoidosis59. 
These immune cells are recruited from the peripheral blood using a chemokines 
gradient of among others IP-10 and RANTES being, shown to be highly elevated in 
active sarcoidosis60. In addition the IL-2 autocrine production is also highly elevated in 
sarcoidosis, leading to further local T-cell proliferation61. Alveolar macrophages also 
accumulate in the lung and have the capacity to function as specialized antigen 
presenting cells62,63. 
The interaction between AM acting as professional antigen presenting cells and 
CD4+ T-helper cells leads to an adaptive response with a characteristic Th1 profile; and 
in the lung tissue the formation of noncaseating granulomas in sarcoidosis64,65 (figure 
2). The formation of granulomas occurs as a result of an immune response against 
unresolved antigen(s) with the aim of limiting inflammation and protecting the 
surrounding tissue. A sarcoid granuloma is formed by the recruitment of macrophages 
and primarily CD4+ T-cells but also some CD8+ T-cells are present on the affected 
organs. The macrophages aggregate and differentiate into epithelioid and 
multinucleated giant cells in the core of the granuloma that is surrounded by T-
cellsmainly CD4+ T-cells66.  
 
 
 
 
 
 
 
 
Figure 2 Schematic view of noncaseating granulomas and possible outcomes (picture 
was taken from Grunewald et.al, Expert Review of Clinical immunology) 
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Stage Finding
0 Normal lungs
I Bilateral hilar lymphadenopathy (BHL)
II BHL + parenchymal infiltration
III Parenchymal infiltrates without BHL 
IV Signs of fibrosis with volume reduction
Several cytokines play a role in the pathogenesis of sarcoidosis. The sarcoid 
granulomatous inflammation is characterized by dominant expression of Th1 cytokines 
such as IFN-γ and interleukin IL-267,68. One key cytokine for the induction of Th1 
response is IL-12 which is secreted by AM and found elevated in the lungs and lymph 
nodes of sarcoidosis patients69. After activation, T-cells release IL-2 that contributes to 
the proliferation of activated T-cells, as well as the production IFN-γ that induces 
macrophage activation. IL-12 and IL-18 are also increased in the lungs of sarcoidosis 
and they further stimulate IFN-γ production68,70. Tumor necrosis factor (TNF)‐α plays a 
major role in the formation and maintenance of the granuloma71. In sarcoidosis the 
spontaneous release of the cytokines TNF-α, IL-1 by activated AM is apparent72. The 
granulomas get either self-resolved or remain in the tissue with a persistent 
inflammatory milieu. The mechanism(s) that result in progression to chronic disease 
and fibrosis are unclear but may be linked to host susceptibility and genetic factors.  
 
1.4.5 Diagnosis 
There is no single diagnostic marker for sarcoidosis as the hallmark of the disease, the 
epithelioid granuloma formation, is unspecific. The diagnosis is based on a combined 
evaluation of clinical symptoms, chest radiographic findings, noncaseating granulomas 
proven in tissue biopsies, and pulmonary function test. The evaluation should be in 
concordance with the WASOG statement on sarcoidosis65. If there is a CD4/CD8 T-cell 
ratio >3.5 in bronchoalveolar lavage fluid this will support the diagnosis. BALF 
findings will also be helpful in discriminating sarcoidosis from other inflammatory lung 
disease59. HLA genotyping may be valuable in predicting the  prognosis of the disorder 
as HLA-DRB1*03 strongly associates with good prognosis73 whereas HLA-DRB1*14 
and-*15 often associates with prolonged disease course 54,73. 
Chest radiographic findings have been used for decades as a means of classifying 
sarcoidosis patients (Table I) 
 
Table I: Radiological stage for diagnosis of sarcoidosis  
 
 
 
 
 
 
 
 
1.4.6 Löfgren’s and non-Löfgren’s sarcoidosis patients 
Lung sarcoidosis patients can be sub-divided into those with Löfgren’s syndrome and 
those without Löfgren’s. Patients with Löfgren’s syndrome have an acute onset with 
erythema nodosum and/or bilateral ankle arthritis, fever and bilateral hilar 
lymphadenopathy with or without parenchymal infiltrates (stage I or II), and usually 
resolve spontaneously within a two-year period74-76. The non-Löfgren’s patients have a 
more insidious disease onset with unproductive cough, dyspnea, fatigue and later 
weight-loss. They commonly have radiological lung changes classified as stage (II-IV)  
28,35,77
.  
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1.5 PROTEOMICS 
Quantitative proteomics is the field of global protein identification and quantification 
from complex samples such as cells, tissues and other biological material, where 
several complementary strategies are available today. Two-dimensional gel 
electrophoresis (2DE) is a method that has been used since 1975 to resolve hundreds of 
proteins simultaneously. The other complementary technique is a gel-free approach 
termed ‘shotgun proteomics’ that uses multidimensional liquid chromatography 
coupled to tandem mass spectrometry. This is also known as bottom-up proteomics 
approach since the protein identification and quantification is performed at the peptide 
level.  
 
1.5.1 Two-dimensional gel electrophoresis (2DE)  
Complex protein samples can be separated using 2DE technique, whereby hundreds of 
proteins may be resolved in a single experiment. Although 2DE has been used since the 
1970s it is still a powerful method, especially for the analysis of Post-Translational 
Modifications (PTMs)78. 2DE in quantitative proteomic provides a comprehensive view 
of a proteome state where alteration in protein levels, splicing and PTMs can be 
investigated 79. 2DE allows protein separation of complex samples according to their 
net charge (isoelectric point) and molecular weight. Using immobilized pH gradient 
strips all proteins are separated (focused) in  a electric field according to the isoelectric 
point80.  
The used of 2DE in quantitative proteomics has been used to the study 
differences in protein patterns of whole proteomes. However quantification has been 
hampered by intrinsic factors related to the 2DE technique such as the low 
reproducibility due to gel-to-gel variation (up to 30% variance). In addition, the silver 
staining normally used to visualize proteins is not suitable for quantitative analysis 
since it has relative low dynamic range of two orders of magnitude and inappropriate 
for biological sample. Taken together, these factors have made 2DE unsuitable for 
accurate quantification analysis until the end of twenty century when a new approach, 
the Differential Gel Electrophoresis (DIGE), with significant improvements became 
available. DIGE is the gel-based approach used for reliable quantification of intact 
proteins and has been available since 200281. The detection limit of the DIGE approach 
is in the range of 150-500pg with linear signal over four orders of magnitude of protein 
concentrations82. Besides the high dynamic range of DIGE the introduction of internal 
standards used for normalization was the most important improvement in order to 
perform reliable quantitative expression analyses using gel-based proteomics83,84.  
 
1.5.2 Mass Spectrometry  
Mass spectrometry (MS) is a technique that measure masses of charged peptides with 
the aim to determine the peptide mass following identification. The principle in mass 
spectrometry is based on the ionization of molecules (peptides) to be able to measure 
their mass-to-charge ratios. Matrix-assisted Laser Desorption Ionization (MALDI) 85 
and electrospray ionization (ESI) 86 are central for protein ionization in MS and their 
development led to award of the Nobel prize in chemistry in 2002. Using the MALDI 
technique, as in our study, the trypsin digested peptides are mixed with a matrix 
(MALDI) that is a low molecular weight that co-crystalizes and become irradiated with 
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a laser beam of appropriate wavelength. Here matrix sublimes and leaves the peptides 
in gas phase. The analytes undergo molecule collision and become often single charged 
protonated H+ and are then accelerated into the high vacuum mass analyzer, Time of 
Flight (ToF)87 to finally reach a detector which measure the ions masses (see Figure 3). 
The MS data are obtained as a peptide mass fingerprint data (PMF) from individual 
proteins. The PMF is then compared with the in silico (theoretical) protein cleavage 
products for the corresponding protein sequence obtained from a protein database e.g. 
the National Center for Biotechnology Information (NCBInr) for protein identification.   
 
 
Figure 3. MALDI-ToF (Matrix-assisted Laser Desorption Ionization time of flight) 
 
The mechanism of MALDI-ToF technique consists of three basic steps: 
 
(i) Formation of a “matrix-analyte cake”: The matrix is always in excess to 
keep the analytes isolated from each-other.   
(ii) Analyte in gas phase: The laser causes excitation so that the analyte and 
matrix is ejected from the metal surface into the gas-phase. 
(iii) Analyte Ionisation: The photo-excited matrix molecules transfer protons 
to the analyte and create ions (mostly positive charged). The ions fly into 
the vacuum system time-of-flight device (TOF), and their masses (m/z) 
are measured. 
 
 
1.5.3 Tandem Mass spectrometry LC-MS/MS 
Tandem mass spectrometry (MS/MS) appeared in the early 2000s and was a 
breakthrough for protein identification in proteomics. These techniques also known as 
bottom-up proteomics or shotgun proteomics are new alternatives becoming more 
widely used to perform differential proteomics with the advantage to obtain huge 
amount data87. In these approaches the total protein content is solubilized and usually 
trypsin-digested into peptides named as precursor ions. This complex peptide soup 
created  is then subjected to nano-scale Liquid Chromatography to allow optimal 
peptide resolution for identification thousands of proteins88.  
The peptides are first separated on the basis of relative hydrophobicity using 
reverse phase C18 column chromatography. Next, in the MS-mode the precursor ions 
get first resolved and then selected for further fragmentation using collision-induced 
dissociation energy (CID) and inert gas. The energy applied here is enough to break 
peptide bonds (weakest bond) and at the same time inefficient to create peptide 
fragments of different lengths. One peptide fragmented sequence yields enough 
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information to match it to a peptide sequence in a protein database on the basis of 
observed and expected fragmentation ions87. The strength of tandem MS is that many 
identified proteins will have multiple matches of MS/MS-derived sequences. The 
Orbitrap MS, being used in our study (paper IV), is the latest technology for tandem 
MS. This employs a new physical principle, namely separating ions in an oscillating 
electric field, and gives greater proteomic coverage due to their much higher resolution, 
thus being ideal for quantification 89,90. 
 
1.5.4 Isotope Tags for relative and absolute quantification 
Global protein quantification can be performed using a peptide-labeling approach. One 
of the most robust approach available today for peptide labeling techniques is Isotope 
Tags for Relative and Absolute Quantification (iTRAQ)91 which  requires tandem MS. 
An advantage is that iTRAQ labels all peptides at the N-terminal and at lysine residues, 
and allows use of 8-plex to simultaneously analyze 8 individual samples in one LC-MS 
analysis. As these tags are isobaric, in the MS-mode the precursor-ions from eight 
differentially labeled samples appear as a single peak thus allowing joint identification. 
Subsequently, in the MS/MS-mode the precursor-ions are fragmented into number 
peptides with different mass to be used for protein sequence analysis. Furthermore, 
single charged reporter ions 113-119 and 121 Da are released and located at regions of 
the mass spectra that do not contain information of the peptide sequencing (at the 110-
130 m/z) which can be used for relative quantitation.  
 
1.5.5 Multivariate Analysis 
Multivariate statistical analysis is a group of methods used to reduce the dimensionality 
of the data, and is very useful in omics methods where the large number of variables 
tested at ones poses the risk of high false positive rates when using traditional 
univariate methods such as t-tests. Principal component analysis PCA was invented in 
1901 by Karl Pearson Karl92. This is an unsupervised method that involves a 
mathematical transformation to convert a set of observations and correlated variables 
into a set of principal components93.  
Partial least squares (PLS) also known as projection to latent structures was 
developed in 1960 by Sture Wold94. PLS regression is a supervised multivariate method 
for assessing relationships between two set of variables; the effector variables (matrix 
X) and the response variable Y. In our studies the X matrix was conformed of all 
proteins identified in proteomics and the Y variable was the diagnosis (healthy or 
sarcoidosis). PLS-regression is particularly suited when the matrix of predictors has 
more variables than observations, and when there are multi-collinearities among X 
variables with emphasis on predicting the response.  
The orthogonal PLS (OPLS) method is a recent modification of the PLS method 
developed by Johan Trygg and Svante Wold95. OPLS separates the systematic variation 
of X matrix into two parts, one that is related to Y-variable and one that is unrelated 
(orthogonal) to Y variable. This partitioning of the X-data provides improved model 
transparency and interpretability, but does not change the predictive power.  
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2 CURRENT INVESTIGATION 
 
 
2.1 AIMS OF THE THESIS 
 
The overall aim of this thesis was to investigate alterations in protein profiles and to 
discover specific diagnostic markers for pulmonary sarcoidosis by applying different 
proteomics techniques. Thereby biological mechanisms related to sarcoidosis 
pathogenesis would be elucidated.  
 
 
The specific aims of individual sections were: 
 
I. to characterize protein expression profiles in bronchoalveolar lavage fluids 
from patients with two granulomatous disorders, sarcoidosis patients (HLA-
DRB1*15 positive) and chronic beryllium disease.  
 
 
II. to quantify different sources of variance related to 2DE techniques and to 
validate the levels of objectivity from the 4th generation image analysis 
software SameSpotsTM. 
 
 
III. to further elucidate new proteins and mechanisms in lung sarcoidosis by 
studying alveolar macrophages using complementary gel-based DIGE and 
gel-free LCMS/MS proteomics approaches. 
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2.2 COMMENTS ON METHODOLOGIES 
 
2.2.1 Patient data and sampling collection 
In the present thesis the experimental work was based on human clinical samples 
including proteins from bronchoalveolar lavage fluids, isolated alveolar macrophages 
and sera from sarcoidosis patients, chronic beryllium disease patients and healthy 
controls, respectively.  
 
Sarcoidosis patients 
All sarcoidosis patients were investigated following a strict protocol at the department 
of respiratory Medicine at Karolinska University Hospital, Stockholm, Sweden. The 
diagnosis and disease phenotype was assessed in concordance with the World 
Association of Sarcoidosis and Other Granulomatous disorders (WASOG) criteria 65. 
Thus the patients had symptom (see 1.4.6) chest radiographic and, pulmonary function 
tests compatible with sarcoidosis. In addition, BALF findings can support the 
diagnosis. Furthermore, the patients were genotyped assessment of HLA class II (paper 
I). In papers III and IV the sarcoidosis patients were also classified according to the 
presence or absence of Löfgren’s syndrome. Löfgren’s syndrome is common (>30%) in 
sarcoidosis patients with Caucasians origin 96. Four patients had Löfgren’s syndrome 
and four were classified as non-Löfgren. Additionally, 18 Löfgren’s and 18 non-
Löfgren’s patients were recruited for ELISA validation. At the time of bronchoscopy 
all patients had active disease and did not receive any steroid treatment. 
 
Chronic Beryllium Disease patients 
BAL samples from five CBD patients were recruited (paper I) from the National Jewish 
Medical and Research Center, Denver, USA. The diagnosis was established by using 
defined criteria including a history of beryllium exposure, presence of a positive blood 
BeLPT-test97 (Beryllium Lymphocyte Proliferation test), the presence of 
granulomatous formation and/or mononuclear cell infiltration in lung biopsies98.  
 
Healthy Controls 
All healthy controls recruited were never-smokers and had normal pulmonary function 
test and chest radiography. Paper I included 5 healthy subjects, papers II and III 7 
subjects each and paper IV six subjects. In addition, 14 healthy subjects were added for 
ELISA to validate the results. All subjects had to be free from airway infections at least 
four weeks prior to investigation. Informed consents were obtained, and all studies 
were approved by the local Ethics committee.  
 
2.2.2 Bronchoscopy 
BAL samples were obtained using a standardized bronchoscopy procedure performed 
at Karolinska University Hospital, Stockholm, Sweden99. BAL samples from CBD 
patients were obtained at the National Jewish Medical and Research Center, Denver, 
CO, USA. Briefly, a bronchoscope was inserted into the right middle lobe under local 
nasobronchial anaesthesia. Aliquots (5 x 50 ml) of sterile saline solution at 37°C were 
instilled. The fluid was then gently recovered by aspiration into a siliconized bottle and 
kept at 4°C. BAL samples were filtered to remove debris using a Dracon net (Miipore, 
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Ireand) and then centrifuged to separate BAL cells (papers II, III, & IV) from the 
supernatant soluble proteins (paper I) (figure 4). Cell pellets were suspended in PBS 
buffer to determine cell viability (using trypan blue exclusion) and to do differential 
cell counting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Workflow of clinical sample used in the studies 
 
 
2.2.3 BAL fluid concentration (paper I)  
In order to use BAL soluble proteins in 2DE analyses (paper I), desalting and protein 
concentration was required. For this purpose Amicon Ultra® (Millipore, Bedford, 
USA) centrifugal filters with an exclusion filter cutoff of >5000 Da were used. First, 
aliquots of 15ml were centrifuged using Amicon Ultra® 10 (45 min at 4000g). Further 
BAL concentration was performed with Amicon Ultra® 4 ml devices (70 min, 4000g). 
Finally, BAL samples were desalted and concentrated from 50 ml to a final volume of 
100µl. Protein concentration determination was performed prior to 2DE.  
 
2.2.4 Alveolar macrophage (papers III & IV) 
Immune cells from the BAL fluid were collected through centrifugation. AMs were 
then isolated using a PercollTM density gradient (GE Healthcare Uppsala, Sweden). A 
two-phase gradient solution with density ρ1= 1.062 g/ml, and ρ2= 1.08 g/ml was 
created in 5ml polyprolylene tubes. Samples were gently layered on the top of the 
system and cells separated through centrifugation (400xg for 20 min) with a recovery 
of >80% and purity of 89.4 ±4.2%. Cells were suspended in RPMI/10% DMSO and 
store at -70°C.  
 
2.2.5 Microsomal preparation (papers II, III, IV) 
Cell pellets containing >4x106 AMs were suspended in 1 mL 0.1 M potassium 
phosphate buffer, pH 7.4, 0.25 M sucrose and protease inhibitors (Complete Mini, 
Roche Diagnostics). The homogenate was sonicated (probe tip sonicator, power: 30%, 
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Bandelin Sonopuls, Buch & Holm) for 4 x 10 seconds on ice. A centrifugation was 
performed at 10000 rpm at 4°C for 10 minutes and the pellet was discarded. The 
protein suspensions were then centrifuged at 100 000 x g at 4°C for 1 hour. The 
resulting supernatants containing soluble proteins were stored at -20°C and the pellets 
were suspended in 500µL 2.5 M NaBr for 45 min on ice with shaking. Another 
centrifugation was performed at 4°C for 1 hour at 100 000 x g. The supernatant 
containing membrane-associated proteins (MAPs) and the pellets containing 
microsomes were stored separately at -20°C until further analysis. 
 
2.2.6 Differential Gel Electrophoresis (papers I, II & III) 
DIGE utilizes three fluorescent Dyes (Cy2, Cy3, and Cy5) that covalently bind to 
Lysine residues on intact proteins using NHS ester chemistry (figure 5). Proteins from 
three samples can be labeled and run simultaneously in one 2DE gel. Classically, Cy3 
and Cy5 are used for sample labeling whereas Cy2 is used as an internal standard100. 
These dyes have identical mass (500Da) and charge +1, but they have distinct emission 
spectra that make it possible to discriminate between each sample used in 
multiplexing83. Proteins coordinates in the 2DE gels are the same for all three samples 
and emission data can be collected using laser scanning. The protein expression levels 
were measured using software analysis Decyder (paper I) and Samespots (papers II and 
III). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Principle and workflow of DIGE 
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Preparative Gels 
Deep Purple™ Total Protein Stain (paper I): gels were first fixed overnight (7.5% 
acetic acid/10% methanol) and then incubated in working solution (Deep purple 1:200 
dilution). Gel images were acquired using the Typhoon 9400 laser scanner, with 
emission Argon laser (ex = 457nm) and band pass emission filter at 610nm (±15nm).   
Coomassie Brilliant Blue staining (paper I): Gels were fixed (50 % ethanol, 10% acetic 
acid for 1 hr), and then stained (Coomassie Brilliant Blue R-250 0.2%, acetic acid 10%, 
ethanol 50%) overnight followed by destaining (10% acetic acid, 10% ethanol for 6h).  
 
2.2.7 Mass Spectrometry (papers I and III) 
Peptides of interest were trypsin-digested prior to mass spectrometry analysis using 
MALDI-ToF. The instrument was calibrated (autodigestive tryptic peptides from 
trypsin) and individual ions were assigned with accurate masses to obtain peptide mass 
fingerprint data (PMF) from individual proteins. The mass spectra were compared with 
the protein sequence database National Center for Biotechnology information (NCBInr) 
having tripsin-digested proteins in silico for protein identification. The statistical 
probability threshold and Z-score are used to accept protein identification as a correct 
match 101.  
 
2.2.8 Peptide labeling iTRAQ (paper IV) 
Membrane-associated proteins were solubilized in 0.5% SDS to determine protein 
concentrations using the DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA). 
Samples were then reduced with DTT (final concentration 5 mM, 30 min at 56° C) and 
alkylated with iodoacetamide (final concentration 0.015 M, 30 min, in the dark) before 
trypsin digestion. Modified sequencing grade Trypsin, (Promega, Madison, USA) was 
used and the samples were incubated at 37°C overnight. For each sample 20 µg of were 
labeled with iTRAQ (8-plex; Applied Biosystems, Foster City, CA, USA) according to 
the experimental design. An internal standard composed of aliquots from each sample 
used was in the study, assuring that all proteins present were represented in the internal 
standard. Excess reagent was removed from the pooled sample using an SCX-cartridge 
(StrataSCX, Phenomenex, Torrence, CA, USA) and the eluate was dried in a vacuum 
centrifuge to further fractionate with narrow IPG-strips.   
 
Peptide fractionation using narrow IPG-strips  
A single dimension separation is not enough to resolve the tens of thousands peptides 
presented in these biological samples. Consequently, narrow IPG 3.5-4.5 offline can 
lead to successful separation and identification of many proteins in complex samples90, 
102
. The integration of narrow IPG-strip and the automatic fractionation into 72 
fractions is high reproducible. 
 
2.2.9 LC-MS/MS analyses (paper IV) 
3µl of each fraction sample were injected on the hybrid LTQ-Orbitrap Velos mass 
spectrometer (Thermo Fischer Scientific, San Jose, USA). Online reversed-phase nano-
LC at 0.4 µl/min for peptide resolution was performed using Solvent A (3 % ACN, 0.1 
% FA); and solvent B (95 % ACN, 0.1 % FA). The gradient created was from 2 % B up 
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to 40 % B in 45 min, followed by a steep increase to 100 % B in 5 min. Samples were 
installed onto the nano electrospray ionisation (NSI). Acquisition proceeded in ~3.5 s 
scan cycles, starting by a single full scan MS at 30000 resolution (profile mode), 
followed by two stages of data-dependent tandem MS (centroid mode): the top 5 ions 
from the full scan MS were selected firstly for collision induced dissociation (CID, at 
35 % energy) with MS/MS detection in the ion trap, and finally for higher energy 
collision dissociation (HCD, at 45 % energy) with MS/MS detection. 
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2.3 RESULTS AND DISCUSSION 
 
The aim of this thesis was to study the protein expression in the lungs of sarcoidosis 
patients with the purpose of identifying relevant proteins markers that could help to 
better understand this disease. Accordingly, previous proteomic studies have reported 
the discovery of altered proteins in sarcoidosis. However, the lack of disease-specificity 
of these proteins has not allowed the identification of disease markers for sarcoidosis.  
  
2.3.1 Paper I 
A quantitative proteomic analysis of soluble bronchoalveolar fluid proteins from 
patients with sarcoidosis and chronic beryllium disease (paper I) 
 
In paper I the aim was to analyze whole protein expression profiles from the alveolar 
lumen in HLA-DRB1*1501 positive sarcoidosis patients, and to compare these to 
healthy controls but also to chronic beryllium disease patients which is another 
granulomatous disease. Both sarcoidosis and CBD patients have several similarities 
regarding the immune response including; the granulomas formation, infiltration of T-
cells in lung parenchyma, and the characteristic Th1 shifted immune response in the 
lungs103. Sarcoidosis patients with HLA-DRB1*1501 tend to have a prolonged, chronic 
inflammation and are at risk of developing fibrosis.  
Using two different controls, i.e. CBD and a healthy group, we searched for 
specific protein markers in sarcoidosis that could differentiate from other 
granulomatous diseases. Aiming at identifying proteins that differ between groups, the 
Student’s T-test with p < 0.05 was considered as significant in our analysis and a total 
of 14 proteins were identified. 
 
Oxidative Stress and Inflammation response 
Oxidative stress is implicated in the pathogenesis of sarcoidosis104, CBD105,106 and other 
respiratory disorders e.g. lung fibrosis, asthma, and chronic obstructive lung disease 
(COPD)107,108. From our results we have identified a set of proteins that correlate to the 
anti-oxidative system (peroxiredoxin 5, hemopexin, α1-antitrypsin, and superoxide 
dismutase) that are altered in granulomatous diseases. These proteins have been 
reported previously in sarcoidosis and CBD106,109,110. Scandinavian sarcoidosis patients 
(Finland) were shown to have peroxiredoxin V highly expressed in their lungs104. The 
other altered mechanism was the inflammatory response where levels of β2-
microglobulin, annexin II, Complement C3, apolipoprotein A1, IgG kappa chain and 
heat shock protein 70 were also found significantly altered. 
In summary, the proteins identified reflect an ongoing inflammatory 
response111,112,113 as well as an up-regulation in oxidative homeostasis104 114-116 in the 
lungs of these patients. Another conclusion was that the type of proteins identified in 
BAL samples was mainly high abundant proteins. This is a frequent problem when 
analyzing complex samples with a wide range in protein concentration117-119. Therefore, 
in the following studies we tried to avoid this by sample treatment enabling us to target 
deeper into the proteome. 
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2.3.2 Paper II 
In the eye of the beholder: does the master see the SameSpots as the novice? 
 
Two-dimensional gel electrophoresis (2DE) has been widely used for separation of 
complex protein samples and subsequent comparison of protein profiles. 2DE has been 
though disadvantaged in quantitative proteomics because of the intrinsic variance 
introduced through the workflow80,120,121. The introduction of internal standard in DIGE 
technique, have reduced most of the gel-to-gel variance of 2-DE, thus allowing 2DE 
technology to be a robust platform for quantitative proteomics100,122,123. With these 
improvements new problems such as software-related variance as well as subjectivity 
of the analysis has become more prominent124-126 and need to be addressed. Although 
the background subtraction is meant to allow more accurate protein quantification, it 
had been shown that these algorithms introduced additional variance to the analysis127. 
The aim of this study was to measure software related variance from available 
background algorithms (average on boundary; AoB, lowest on boundary; LoB and 
mode of none spot; MoNS) as well as the experimental variance from traditional single 
stained technique, respectively. As showed in figure 6 different variance from 
background subtraction algorithms were measured performed by two independent 
users. The default algorithm LoB introduced the least amount of variance (Lab-user: 
CVmean=2.5%; Expert: CVmean=3.1%), the algorithm AoB showed (Lab-user: 
CVmean=2.8%; Expert: CVmean=3.8%) and finally, the algorithm MoNS introduced 
the highest variance (Lab-user: CVmean=5.5%; Expert: CVmean=7.2%). Comparing 
these results with early software these variance shows significant improvements127,128. 
 
 
 
 
 
 
              
 
Figure 6: Software, technical and biological variance measured in 2DE 
 
In addition, single-stained gel variance was measured as a technical related 
variance. For single gels, spot-based ratio normalization was used whereas for DIGE 
the ratiometric normalization (including an internal standard) was applied. As showed 
in the figure 6 the normalization method of choice had a much larger effect in variance 
introduced to the analysis. Finally, we correlated the total spot-volumes identified from 
expert and lab-user, using partial least squares of latent structures (PLS) analysis to see 
levels of similarities and objectivity of the analysis. Accordingly, the PLS demonstrates 
a strong correlation (correlation coefficients near to 1.0) for the contribution of proteins 
between the two analyses, showing that the outcome of the analysis is largely user-
independent and highly objective.  
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2.3.3 Paper III  
A proteomic approach to study alveolar macrophages from sarcoidosis patients 
 
Herein we studied alterations in the expression levels of AM soluble proteins in 
pulmonary sarcoidosis. Using 2DE couple with MS and MSMS we identified a set of 
new proteins that were differentially expressed (p<0.05) in patients with sarcoidosis as 
compared to healthy controls (Table II). 
Improvements in sample preparation including the isolation of AMs from other 
BAL cells129 and subsequent protein fractionation129 has allowed identification of new 
set proteins not previously reported in sarcoidosis130-133.  
 
 
Table II 
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Pathway analysis  
We found that the Fcγ receptor-mediated phagocytosis in macrophages (p=1.3*10-5), 
and the clathrin-mediated endocytosis signalling (p=0.0019) were both upregulated in 
sarcoidosis. The proteins rab11, phospholipase D, diacylglycerol kinase, dynein and 
gamma interferon lysosome transferase were also up-regulated, and they are associated 
with Fcγ receptor-mediated phagocytosis in macrophages. Several studies show the 
functionality of these proteins in phagocytosis134-137. Dynein has been reported to be 
involved in internalization of exogenous pathogens during macropinocytosis138.Gamma 
interferon-inducible lysosomal thiol reductase (gilt) was found to be, upregulated in 
sarcoidosis;  it cleaves disulphide-bounds of antigens and is implicated in MHC-II 
antigen processing139,140.  
In the clathrin-mediated endocytosis signalling pathway AP-2, actin and rab-11 
were up-regulated: AP-2 is highly active in endosomal trafficking involved in MHC 
class II antigen presentation141 and is related to the antigen presenting function on AMs 
in sarcoidosis29. The Rab family, approximately composed of 70 related proteins 
identified in humans, regulates steps during membrane traffic, vesicle formation and 
membrane fusion142. Rab11 has been reported to be associated with the recycling 
compartment, post-Golgi vesicles, and the trans-Golgi network in early endosomes143. 
So , the Fcγ receptors (FcγR) play a crucial role in the innate response as cellular 
phagocyte effector machinery2,144. In sarcoidosis, AMs have been shown to be activated 
antigen-presenting cells able to phagocyte foreign antigens and present epitopes on 
HLA-molecules to the T-cells and induce a potent adaptive response29. 
 
Multivariate analysis 
Multivariate modeling was applied to identify protein candidate markers for 
sarcoidosis. When response variable diagnosis was correlated with protein-spot 
abundances, we constructed a model able to explain 86% of the variance with a 
predictive power of 41% (R2Y=0.86, Q2=0.41) (figure7). When using variables 
important to the projection (VIP-plot), to rank the important variable according to their 
contribution to the model; valosin containing protein (vcp) came out as the most 
relevant variable for discriminating between sarcoidosis and the healthy group. 
 
Figure 7. Score-plot (left graph) shows the group clustering for sarcoidosis (S1-7) and 
healthy (H1-7) respectively. The load-plot (righ panel) shows the proteins and their 
correlation to the groups. Proteins located at the right area of the plot correlated directly 
with sarcoidosis group, whereas those proteins at the left area correlated inversely. 
   21 
VCP
Sarcoidosis Controls
0.6
0.8
1.0
1.2
1.4
        p=0.007
No
rm
ali
se
d 
vo
lum
e
 
 
 
 
 
 
 
 
 
 
Figure 8: Valosin containing protein upregulated in DIGE expression analysis 
 
2DE image analysis revealed valosin contained protein (vcp) to be up-regulated in 
sarcoidosis (p=0.007) (figure 8). vcp is involved in several relevant functions such as 
membrane fusion145, regulation of transcriptional activation NFқB146, apoptosis147,148 
and the proteosomal degradation system (ERAD)149 150,151.  
In summary, we reported here the identification of 25 unique proteins from the 
AMs altered in sarcoidosis. In the network analysis 11 proteins were found linked to 
the 26s proteasome and the NFkB complex nodes; 8 up regulated and 3 down regulated 
in sarcoidosis. Two pathways associated to phagocytosis were upregulated in 
sarcoidosis; the Fcγ receptor mediated phagocytosis in macrophages, and the clathrin-
mediated endocytosis signalling. Additionally, the up regulation of myd 88 and gilt in 
AMs from sarcoidosis patients may suggest the possible presence microorganism 
agents. Myd is in tight connection with TLR signalling and gilt strictly specific for 
MHC II antigen processing. These findings represent a step forward in understanding 
the complexity of sarcoidosis pathogenesis, and help to better understand mechanisms 
that could be of relevance in the development of sarcoidosis. Further validation of these 
data in larger sample material is required in order to be able to suggest them as 
potential markers.  
 22 
 
2.3.4 Paper IV  
Proteomic analysis of membrane-associated proteins in alveolar macrophages from 
patients with pulmonary sarcoidosis 
 
Results from Paper III revealed a differential analysis of soluble proteins from AMs 
using the gel-based technique DIGE and highlighted the discovery of a new set of 25 
proteins and pathway alterations. Several proteomics studies have reported the benefits 
in applying sample fractionation prior to expression analysis in order to reduce protein 
complexity and to enable deeper insight into the proteome for discovery of protein 
biomarkers or to identify relevant associated mechanisms. 
In this paper we performed a Shotgun proteomics approach using LTQ-Orbitrap 
Velos mass spectrometer on membrane associated proteins (MAP). This new technique 
is capable to identify and in a relative way quantify large numbers of proteins 
simultaneously. Accordingly, 1650 proteins were identified from which 423 proteins 
(expressed in all samples) have been possible to perform differential analyses using 
iTRAQ labeling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Network analysis showed proteins altered in sarcoidosis linked to the NFkB 
complex. Green represents decreased level and red an increased level in sarcoidosis. A 
total of 31 proteins, 14 up-regulated and 17 down-regulated in sarcoidosis were linked 
directly or indirectly to NFkB. 
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Pathway analysis: 
  
Mitochondrial dysfunction in Non-Löfgren’s sarcoidosis patients 
Ingenuity system analysis permits the characterization of pathway alterations in 
sarcoidosis samples. Down- regulation of the oxidative phosphorylation pathway in the 
mitochondrial respiration system was observed in sarcoidosis (p-value 1.02x10-10) 
(figure 10). Interestingly, when the patients were sub grouped according to their clinical 
phenotype into Löfgren’s and non-Löfgren’s, we found this pathway up-regulated in 
Löfgren’s patients but down-regulated in non-Löfgren’s patients.  
 
 
Figure 10. Mitochondrial dysfunction in the electron transport in Non-Löfgren’s 
sarcoidosis patients 
 
Non-Löfgren’s sarcoidosis patients have a tendency to associate with unresolved 
chronic inflammation, with elevated levels of reactive oxygen species (ROS). They 
often present a more advanced radiological stage (III-IV) and have an increased risk of 
developing fibrosis. 
 It is known that excessive levels of ROS cause tissue damage, and redox 
imbalance has also been associated with other lung disease such as, chronic 
inflammation in COPD152, asthma 153, lung fibrosis and cancer 107. In sarcoidosis, ROS 
species such as superoxide anion in lungs has shown to be highly elevated. Even a 
systemic oxidative stress has been reported in pulmonary sarcoidosis154.  
Furthermore, this redox imbalance has been shown to cause mitochondrial 
proteins damage leading to increased protein degradation and dysfunction in 
mitochondria 155,156. These results suit well with the clinical phenotype of these non-
Löfgren’s patients. This down-regulation of oxidative phosphorilation and 
mitochondrial dysfunction is correlated to high level of ROS in lungs; therefore we 
suggest that this could be of therapeutic importance. Since it is known that systemic 
steroids do not help in advanced stage of sarcoidosis, it may be that antioxidant drugs 
may help to reduce the chronic inflammation in lungs.  
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Up-regulation of the phagocytosis pathways in sarcoidosis 
Phagocytosis is complex and comprises among other events particle binding, actin 
rearrangement, pseudopod extension, membrane recycling and phagosome closure. In 
concordance with the previous study (paper III); here we also found the up-regulation 
of Clathrin-mediated endocytosis signaling in AMs from sarcoidosis patients (p-value 
9.64x10-9). Clathrin-dependent endocytosis is a process by which cells internalize 
molecules through the inward budding of plasma membrane vesicles containing 
proteins with receptor sites specific to the molecules being internalized. This 
mechanism is relevant to the MHC II-peptide mechanism157,158. Ingenuity system 
showed clathrin-mediated endocytosis signaling increased levels in sarcoidosis of the 
adaptor-related protein (complex 1 beta 1 subunit AP1B1; complex 2 alpha 1 subunit, 
AP2A1; and complex 2 sigma 1 subunit AP2S1), member RAS oncogene family 
(RAB11A, RAB4A, RAB4B, RAB5C, RAB7A), clathrin (light-chain CLTA, and 
heavy-chain CLTC), actin like protein-3; ARP-3, actin beta, ACTB; and actin alpha, 
ACTA1. In addition, heat shock 70kDa protein 8, HSPA8; and transferrin; TF, were 
decreased in sarcoidosis. 
Additionally, we have also found similar up regulation on the Fcγ receptor-
mediated phagocytosis in macrophage pathway in sarcoidosis (p-value 1.47x10-5) but 
in this study with even more proteins identified in this pathway. Here nine proteins 
were upregulated (Actin alpha-1, ezrin, actin-beta, actin related protein-3 homolog, 
myosine VA, rab-11, ras-related C3 botulinum toxin substrate 1, v-src sarcoma viral 
oncogene homolog, talin-1) and two were down-regulated (vesicle-associated 
membrane protein-3,heme oxigenase-1) in sarcoidosis. 
Accordingly, these two complementary pathways were up-regulated in both the 
Löfgren’s and non-Löfgren’s sarcoidosis patients, as reported in paper III. These 
pathways are part of the mechanism that mediates internalization of pathogens, for 
instance bacteria, into membrane-derived vacuoles and the phagosome system, finally 
leading to degradation of pathogens and the presentation of specific antigens to 
memory T-cells in the lungs6. This results suggest the hypothesis of an infectious agent 
in sarcoidosis, where AMs as APC constantly phagocyte, process and present the 
antigens T cells in the lungs.  
 
 
Predictive OPLS model to discriminate sarcoidosis from the healthy group 
Using 423 proteins the orthogonal projection to latent structures (OPLS) was performed 
to identify, if possible, a model able to discriminate sarcoidosis patients from healthy 
controls. We constructed a model with a subset of 13 putative biomarker proteins that 
resulted in a highly predictive model (Q2 = 0.72) with an overall model p-value of 
0.0009 (figure 11). 
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Figure 11a.OPLS Scoring-plot showing group clustering in first component t[1]. X-axis 
included all subjects (sarcoidosis n=8, and healthy n=6) without outliers (±2SD). Figure 
11b. Loading-plot shows the proteins group that discriminate sarcoidosis and healthy. 
The plot shows the direct correlated variables (bars above zero-level; n=4) and indirect 
correlated variables (n=9). 
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2.4 GENERAL CONCLUSIONS  
This thesis has focused on searching for new proteins altered in the lung of sarcoidosis 
patients using proteomics technologies in order to increase the understanding of the 
pathology behind the disease. Conclusions can be summarized as follow: 
 
• In the technical study aimed to measure source of variance in a 2DE approach 
we reported improvements in reduced variance introduced to 2DE experiments 
from background algorithms; the removal of experimental variance when using 
DIGE approach and overall improvements in the objectivity of the analysis 
using this 4th generation software analysis software, SameSpots. 
 
• Looking at soluble proteins from the lungs of sarcoidosis and CBD patients we 
could observe alterations of a set of proteins which in general reflected the 
activation of the inflammatory process. The up-regulation of complement C3, 
β2-microglobulin and IgG may indicate a pronounced opsonisation mechanism 
against microbial pathogens in the innate immune response. In addition, the 
anti-oxidants peroxiredoxin 5, α1-antitrypsin were also up regulated, reflecting 
the high levels of reactive oxygen species (ROS) in the lungs of these 
granulomatous disorders.  
 
By applying complementary proteomic techniques on different protein fractions from 
isolated AMs, we could identify and quantify a new set of proteins that have not been 
described previously in sarcoidosis pathology.  
 
• In a DIGE study investigating the soluble proteome of AMs, we identified 25 
proteins to be altered in sarcoidosis. When applying pathway analyses we found 
the Fcgamma receptor-mediated phagocytosis pathway and the clathrin-
mediated endocytosis signaling pathway to be up regulated in sarcoidosis. In 
the complementary shotgun proteomics analyses, investigating the AM 
membrane associated proteome, we found 80 proteins altered and accordingly 
the same pathways were identified. These pathways were also up regulated in 
sarcoidosis compared to healthy controls.  
 
Sarcoidosis can be divided into Löfgren´s syndrome and non-Löfgren´s syndrome 
patients, having different clinical phenotype and outcome. Patients with Löfgren’s often 
recover spontaneously within 2 years, whereas non-Löfgren’s usually having a 
prolonged unresolved inflammation in the lungs. When comparing these subgroups we 
found: 
 
• Down-regulation of the oxidative phosphorylation pathway from the 
mitochondrial respiration system in non-Löfgren’s, but up-regulation in 
Löfgren’s patients. This mitochondrial dysfunction could lead to an imbalance 
in the optimal AM function as APC in non-Löfgren’s sarcoidosis patients. In 
addition, this mitochondrial dysfunction only observed in non-Löfgren’s 
patients could partly be related to the unresolved inflammation and prolonged 
disease course observed. Furthermore, this imbalance in oxidative homeostasis 
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could potentially be associated with the increased risk of development of 
fibrosis observed in this sarcoidosis phenotype.  
 
• We observed in both studies on AMs that the expression pattern in Löfgren’s 
patients was more homogeneous as compared to the non-Löfgren. This could be 
translated clinically as Löfgren’s syndrome is a distinct phenotype presenting 
with a typical acute onset, whereas non-Löfgren’s patients is a more 
heterogeneous group involving different clinical manifestations and may 
accordingly involve multiple mechanisms. 
 
Searching for molecular markers we performed multivariate analysis and found a set of 
proteins in a model able to discriminate sarcoidosis from healthy. A subset of 13 
putative biomarker proteins resulted in a highly predictive model (Q2 = 0.72) with an 
overall model p-value of 0.0009.  
 
• Three of these proteins are involved in endocytic transport; mitogen-activated 
protein kinase scaffold protein 1, regulator complex protein PDRO and ras 
related protein Rab-7a. One of the proteins, the complement component 1 Q 
subcomponent-binding protein, is involved in host-virus interactions 159. The 
rest of the 13 proteins are involved in DNA repair, alcohol metabolism, protein 
folding and ribosomal activity.  
 
Taken together, these studies have identified new proteins potentially involved in the 
molecular mechanisms of sarcoidosis disease. A limitation in numerous proteomics 
studies has been the inability to verify the biological relevance of the findings, which 
may hamper the utility of the results. The similarity of the findings from the 
complementary proteomics approaches presented in this dissertation may serve as a 
confirmation of the biological relevance of our results.  
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